DAPT using cilostazol, a therapeutic option for prevention of recurrent stroke without bleeding risk: Study

Written By :  MD Editorial Team
Medically Reviewed By :  Dr. Kamal Kant Kohli
Published On 2021-11-22 03:30 GMT   |   Update On 2023-10-19 10:34 GMT

Japan: Dual antiplatelet therapy (DAPT) is the combination of aspirin and one ADP-receptor blocker. To reduce the risk of acute stent thrombosis the period of DAPT is preferable with prasugrel or ticagrelor. The long-term benefit of dual antiplatelet therapy (DAPT) over single antiplatelet therapy (SAPT) for the prevention of recurrent stroke isn't known in patients with intracranial...

Login or Register to read the full article

Japan: Dual antiplatelet therapy (DAPT) is the combination of aspirin and one ADP-receptor blocker. To reduce the risk of acute stent thrombosis the period of DAPT is preferable with prasugrel or ticagrelor. The long-term benefit of dual antiplatelet therapy (DAPT) over single antiplatelet therapy (SAPT) for the prevention of recurrent stroke isn't known in patients with intracranial arterial stenosis.

A randomized trial by Shinichiro Uchiyama and team revealed that DAPT using cilostazol is superior to SAPT with clopidogrel or aspirin for the prevention of recurrent stroke and vascular events without increasing bleeding risk among patients with intracranial arterial stenosis after stroke. The findings of the study are published in the Journal of the American Heart Association (JAHA).

The objective of the study was to compare the efficacy and safety of DAPT with cilostazol and clopidogrel or aspirin to those of SAPT with clopidogrel or aspirin in patients with intracranial arterial stenosis.

The patients were recruited from Cilostazol Stroke Prevention Study for Antiplatelet Combination trial, a randomized controlled trial in high‐risk Japanese patients with ischemic stroke. The researchers compared the vascular and hemorrhagic events between DAPT and SAPT in patients with ischemic stroke and symptomatic or asymptomatic intracranial arterial stenosis of at least 50% in a major intracranial artery.

Patients were divided into two groups: 275 were assigned to receive DAPT and 272 patients SAPT. 

The researchers found that the risks of ischemic stroke (hazard ratio [HR], 0.47); and a composite of stroke, myocardial infarction, and vascular death (HR, 0.48) were lower in DAPT than SAPT, whereas the risk of severe or life‐threatening bleeding (HR, 0.72) did not differ between the 2 treatment groups.

Uchiyama and team concluded that "DAPT using cilostazol was superior to SAPT with clopidogrel or aspirin for the prevention of recurrent stroke and vascular events without increasing bleeding risk among patients with intracranial arterial stenosis after stroke."

Reference: https://doi.org/10.1161/JAHA.121.022575

Tags:    
Article Source : Journal of the American Heart Association

Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News